Diverted products include which of the following scenarios?

• A. A product that left the US pharmaceutical supply chain and is reintroduced in the US in a transaction with a trading partner; or a product labeled for sale in a non-US market and introduced into the US pharmaceutical supply chain through a transaction with a trading partner.
• B. A product that was recalled for safety concerns.
• C. A product that is counterfeit.
• D. A product that is expired.

Answer: (A)

The main idea being tested is how diversion of pharmaceutical products is defined—moving drugs into the US supply chain through channels not intended for US distribution, often via trading partners or from non-US markets.

The scenario that fits best describes products that left the US supply chain and are reintroduced in the US through a transaction with a trading partner, or products labeled for non-US markets that are brought into the US via a trading partner. These illustrate diversion because the product is entering the US channel through an alternate route or market, not through the normal, authorized US distribution path.

The other situations describe safety recalls, counterfeit goods, or products that are past their shelf life, which are issues of quality, authenticity, or expiration rather than diversion from the intended distribution route.